surmount-1 trial tirzepatide non-diabetic weight loss once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 surmount-1 trial tirzepatide non-diabetic obesity

Researchers studying tirzepatide for weight loss started noticing inflammatory markers dropping, and not just because participants were losing weight

Clinical studies and real-world patient data show that tirzepatide often leads to greater weight loss in a shorter amount of time

Lm reversed gut dysbiosis and restored the abundance of commensal bacteria genera ( Faecalibaculum , Coriobacteriaceae UCG 002, Lactococcus , Negativibacillus , Turicibacter , Ruminiclostridium 6, Parasutterella , Eubacterium xylanophilum group, Ruminococcaceae UCG 010, and Staphylococcus ) which are mainly SCFAs producers resulting in enhanced intestinal barrier integrity

In my experience, using GH/HGH long-term for too long can cause insulin resistance and lead to gestational diabetes